Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;24(8):457-469.
doi: 10.1007/s11882-024-01160-y. Epub 2024 Jul 19.

New insights into chronic inducible urticaria

Melba Muñoz  1   2 , Lea Alice Kiefer  1   2 , Manuel P Pereira  1   2 , Mojca Bizjak  3 , Marcus Maurer  4   5
Affiliations
Review

New insights into chronic inducible urticaria

Melba Muñoz et al. Curr Allergy Asthma Rep. 2024 Aug.

Abstract

Purpose of review: Chronic inducible urticaria (CIndU) is a group of long-persisting and challenging to manage diseases, characterized by recurrent wheals and angioedema induced by definite triggers. In this review, we address recent findings on CIndU pathogenesis, diagnosis as well as its treatment, and we discuss novel potential targets that may lead to the development of more effective therapies for CIndU patients.

Recent advances: Meaningful advances in the understanding of its pathogenesis have been reported in the last decades. Novel CIndU-specific patient-reported outcome measures enable a closer and better evaluation of patients. CIndU is a hard-to-treat disease that highly impairs quality of life (QoL) of affected patients. Provocation tests allow to diagnose CIndU subtypes. The only licensed and recommended treatment for CIndU are second generation non-sedating H1-antihistamines, which lack efficacy in many cases. Omalizumab off-label use has been assessed in all types of CIndU with overall good outcomes. Promising emerging therapies currently assessed in chronic spontaneous urticaria are paving the path for novel treatments for CIndU.

Keywords: Cholinergic; Cold; Delayed pressure; Dermographism; Heat; IgE; Inducible urticaria; Mast cell; Provocation; Solar; Vibratory.

PubMed Disclaimer

Conflict of interest statement

MMu reports personal fees from Astra Zeneca, personal fees from Celldex Therapeutics, research grants from Roche, personal fees from Takeda, personal fees from GA²LEN, personal fees from UNEV, outside the submitted work.

LAK reports no relevant conflicts of interest.

MMP reports personal fees from AbbVie, grants from Almirall, personal fees from Beiersdorf, personal fees from Celltrion, personal fees from Eli Lilly, personal fees from GA2LEN, personal fees from Galderma, personal fees from Menlo Therapeutics, personal fees from Novartis, personal fees from P.G. Unna Academy, personal fees and other from Sanofi, personal fees and other from Trevi Therapeutics, other from Allakos, other from Aslan Pharmaceuticals, other from Celldex Therapeutics, other from Incyte, outside the submitted work.

MB has served as a speaker and advisor for Novartis.

MM reports grants and personal fees from Allakos, personal fees from Aralez, personal fees from Alnylam, grants from AstraZeneca, grants and personal fees from BioCryst, grants from Blueprint, personal fees from CSL Behring, grants and personal fees from FAES, grants and personal fees from Genentech, personal fees from Kalvista, grants and personal fees from Menarini, grants from Leo Pharma, grants and personal fees from Moxie, grants and personal fees from MSD, grants from Pharming, personal fees from Pharvaris, grants and personal fees from Roche, grants and personal fees from Sanofi, grants and personal fees from Shire/Takeda, grants and personal fees from UCB, grants and personal fees from Uriach, outside the submitted work.

Figures

Fig. 1
Fig. 1
Provocation tests for CIndU diagnosis
See this image and copyright information in PMC

References

    1. Harris BW, Crane JS, Schlessinger J. Solar Urticaria. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023. 2024 Jan–. PMID: 28723015 - PubMed
    1. Kolkhir P, et al. Urticaria Nat Rev Dis Primers. 2022;8(1):61. 10.1038/s41572-022-00389-z - DOI - PubMed
    1. Terhorst-Molawi D, et al. Anti-KIT antibody barzolvolimab reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023;78(5):1269–79. Findings from this study show that mast cells are indispensible for the development of SD and ColdU. 10.1111/all.15585 - DOI - PubMed
    1. Kaplan AP, et al. Idiopathic cold urticaria: in vitro demonstration of histamine release upon challenge of skin biopsies. N Engl J Med. 1981;305(18):1074–7. 10.1056/NEJM198110293051808 - DOI - PubMed
    1. Murphy GM, et al. Symptomatic dermographism (factitious urticaria)–passive transfer experiments from human to monkey. Br J Dermatol. 1987;116(6):801–4. 10.1111/j.1365-2133.1987.tb04898.x - DOI - PubMed

LinkOut - more resources